The price-to-earnings ratio for Corcept Therapeutics Inc (NASDAQ: CORT) is above average at 40.21x, Company’s 36-month beta value is 0.46.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 1 as “sell.”
The public float for CORT is 89.95M, and currently, short sellers hold a 24.13% ratio of that floaft. The average trading volume of CORT on October 03, 2024 was 847.17K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CORT) stock’s latest price update
Corcept Therapeutics Inc (NASDAQ: CORT)’s stock price has decreased by -1.16 compared to its previous closing price of 45.86. However, the company has seen a 4.74% increase in its stock price over the last five trading sessions. zacks.com reported 2024-10-02 that Here, we are discussing some reasons why investing in CORT stock now may turn out to be a prudent move.
CORT’s Market Performance
Corcept Therapeutics Inc (CORT) has seen a 4.74% rise in stock performance for the week, with a 30.94% gain in the past month and a 50.70% surge in the past quarter. The volatility ratio for the week is 4.41%, and the volatility levels for the past 30 days are at 4.57% for CORT. The simple moving average for the last 20 days is 12.37% for CORT stock, with a simple moving average of 54.94% for the last 200 days.
Analysts’ Opinion of CORT
Many brokerage firms have already submitted their reports for CORT stocks, with Truist repeating the rating for CORT by listing it as a “Buy.” The predicted price for CORT in the upcoming period, according to Truist is $38 based on the research report published on November 06, 2023 of the previous year 2023.
SVB Securities, on the other hand, stated in their research note that they expect to see CORT reach a price target of $25. The rating they have provided for CORT stocks is “Market Perform” according to the report published on April 11th, 2023.
Piper Sandler gave a rating of “Overweight” to CORT, setting the target price at $27 in the report published on April 04th of the previous year.
CORT Trading at 22.25% from the 50-Day Moving Average
After a stumble in the market that brought CORT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.99% of loss for the given period.
Volatility was left at 4.57%, however, over the last 30 days, the volatility rate increased by 4.41%, as shares surge +34.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +32.54% upper at present.
During the last 5 trading sessions, CORT rose by +5.59%, which changed the moving average for the period of 200-days by +53.61% in comparison to the 20-day moving average, which settled at $40.92. In addition, Corcept Therapeutics Inc saw 39.56% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CORT starting from Robb Gary Charles, who sale 11,000 shares at the price of $46.28 back on Oct 01 ’24. After this action, Robb Gary Charles now owns 22,772 shares of Corcept Therapeutics Inc, valued at $509,080 using the latest closing price.
Robb Gary Charles, the Officer of Corcept Therapeutics Inc, proposed sale 11,000 shares at $46.28 during a trade that took place back on Oct 01 ’24, which means that Robb Gary Charles is holding shares at $509,080 based on the most recent closing price.
Stock Fundamentals for CORT
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.98 for the gross margin
The net margin for Corcept Therapeutics Inc stands at 0.22. The total capital return value is set at 0.21. Equity return is now at value 24.55, with 20.17 for asset returns.
Based on Corcept Therapeutics Inc (CORT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 21.83. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 35.73.
Currently, EBITDA for the company is 109.64 million with net debt to EBITDA at -0.95. When we switch over and look at the enterprise to sales, we see a ratio of 8.21. The receivables turnover for the company is 10.15for trailing twelve months and the total asset turnover is 0.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.57.
Conclusion
In a nutshell, Corcept Therapeutics Inc (CORT) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
